A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ [hydrochlorothiazide] with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension.
Latest Information Update: 29 Dec 2014
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
- Indications Essential hypertension; Hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual end date (July 2006) added as reported by ClinicalTrials.gov (Extension trial: NCT00294710).
- 07 Nov 2011 Actual end date (July 2006) added as reported by ClinicalTrials.gov (Extension trial: NCT00294710).
- 05 Nov 2005 New trial record.